Research article summary (published 27 Feb 2006):

Emerging drugs for premature ejaculation.

Full Abstract

Lifelong premature ejaculation (PE) is a frequent male sexual dysfunction and is thought to be mediated in part by disturbances of serotonergic (5-hydroxytryptamine; 5-HT) neurotransmission and ejaculation-mediating 5-HT receptors in the CNS. The aetiology of the dysfunction is unclear, but probably includes neurobiological and environmental factors. Lifelong PE is a syndrome characterised by a cluster of symptoms. Rapid ejaculations become manifest around the first sexual encounters in puberty or adolescence. Intravaginal ejaculation latency time usually occurs within 30-60 s, or maximally within 2 min after vaginal penetration, is present with nearly every sexual partner, and remains similar throughout life or may aggravate during ageing. The syndrome may lead to secondary psychological, sexual and relationship problems. Daily treatment with some selective serotonin re-uptake inhibitors (SSRIs) leads to strong ejaculation delay, but may be accompanied by side effects. New treatment with SSRIs with a short half-life (if approved) for on-demand use 1-2 h prior to coitus exerts less ejaculation-delaying effects than daily SSRI strategies. Animal studies have shown that strong, immediate ejaculation delay may be induced by the combination of an SSRI with a 5-HT(1A) receptor antagonist. The combination of an SSRI and any other compound that immediately strongly raises 5-HT neurotransmission may form the basis for the development of new on-demand drugs to treat PE.

Author information

Author/s: Waldinger, Marcel D (MD);

Affiliation: Department of Psychiatry and Neurosexology, HagaHospital Leyenburg, Leyweg 275, 2545 CH, The Hague, The Netherlands. md(-atsign-)waldinger.demon.nl

Journal and publication information

Publication Type: Journal Article; Review

Journal: Expert opinion on emerging drugs (Expert Opin Emerg Drugs), published in England. (Language: eng)

Reference: 2006-Mar; vol 11 (issue 1) : pp 99-109

Dates: Created 2006/02/28; Completed 2006/11/14; Revised 2007/11/15;

PMID: 16503829, status: MEDLINE (last retrieval date: 2/18/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Administration, Oral Animals Benzylamines - administration & dosage; pharmacokinetics; therapeutic use Central Nervous System - drug effects; metabolism Clinical Trials as Topic Drug Evaluation, Preclinical Drug Therapy, Combination Ejaculation - drug effects Half-Life Humans Male

Male Naphthalenes - administration & dosage; pharmacokinetics; therapeutic use Paroxetine - administration & dosage; pharmacokinetics; therapeutic use Piperazines - pharmacology Pyridines - pharmacology Receptor, Serotonin, 5-HT1A - antagonists & inhibitors; metabolism Serotonin - metabolism Serotonin Antagonists - pharmacology Serotonin Plasma Membrane Transport Proteins - drug effects; metabolism Serotonin Uptake Inhibitors - administration & dosage; pharmacokinetics; therapeutic use Sexual Dysfunction, Physiological - drug therapy; metabolism

Associated Chemicals: Benzylamines (0) ; Naphthalenes (0) ; Piperazines (0) ; Pyridines (0) ; Serotonin Antagonists (0) ; Serotonin Plasma Membrane Transport Proteins (0) ; Serotonin Uptake Inhibitors (0) ; Receptor, Serotonin, 5-HT1A (112692-38-3) ; dapoxetine (119356-77-3) ; WAY 100635 (146714-97-8) ; Serotonin (50-67-9) ; Paroxetine (61869-08-7)

Related articles

These are the highest related articles currently in the database:

• Lifelong premature ejaculation: definition, serotonergic neurotransmission and drug treatment. 31 May 2005
• Pharmacokinetic and pharmacodynamic features of dapoxetine, a novel drug for 'on-demand' treatment of premature ejaculation. 30 Jan 2006
• Dapoxetine treatment of premature ejaculation. 23 Nov 2006
• Single- and multiple-dose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation. 27 Feb 2006
• Comparison of dapoxetine versus paroxetine in patients with premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. 30 Aug 2006
• Medical therapy for premature ejaculation. 7 Sep 2006
• Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. 7 Sep 2006
• Regarding Waldinger and Schweitzer's "premature ejaculation and pharmaceutical company-based medicine: the dapoxetine case". 30 Mar 2008
• Pharmacologic treatment of rapid ejaculation: levels of evidence-based review. 30 Aug 2006
• Premature ejaculation and pharmaceutical company-based medicine: the dapoxetine case. 30 Mar 2008

See 100+ related articles.

Related Article Map

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a large map of 100+ related articles.